Literature DB >> 18571450

Pericardial and abdominal fluid accumulation in congenital disorder of glycosylation type Ia.

Gerben Truin1, Mailys Guillard, Dirk J Lefeber, Jolanta Sykut-Cegielska, Maciej Adamowicz, Esther Hoppenreijs, Rob C A Sengers, Ron A Wevers, Eva Morava.   

Abstract

The association of fetal hydrops with Congenital Disorders of Glycosylation (CDG) has been reported previously. Pericardial fluid accumulation and ascites were also observed in a few young patients with CDG type Ia. Here we describe the clinical and biochemical features in three children developing life-threatening extravascular fluid accumulation. All patients carried severe PMM2 mutations comparable to the earlier reported patients with fetal hydrops. One patient was successfully treated with a pericardial-pleural shunt placement. Pericardial fluid accumulation and generalized oedema resolved temporarily in the other two children on regular albumin infusions and the use of diuretics. Sequential abdominal punctures were unsuccessful in the treatment of the extensive ascites production. The use of non-steroid anti-inflammatory agents and the application of high dose steroids had no clinical effect. Severe extravascular fluid accumulation progressed to decompensation and death. Biochemical investigations of the abdominal fluid and pericardial fluid demonstrated a high extracellular protein concentration, increased cytokine concentrations and an abnormal transferrin isoelectric focusing pattern characteristic of CDG type I. Our results are consistent with a local activation of the cytokine pathways and subsequent protein transport through the endothelial surface to the extravascular space. Normal glycosylation of cell surface proteins is essential for the normal fluid balance and protein transport through the pericardial and peritoneal membrane. Future therapeutic efforts should be directed to inhibit the abnormal immune response and excessive protein transport in this life-threatening complication of CDG syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571450     DOI: 10.1016/j.ymgme.2008.05.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

Review 1.  Recognizable phenotypes in CDG.

Authors:  Carlos R Ferreira; Ruqaia Altassan; Dorinda Marques-Da-Silva; Rita Francisco; Jaak Jaeken; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2018-04-13       Impact factor: 4.982

2.  Mild clinical and biochemical phenotype in two patients with PMM2-CDG (congenital disorder of glycosylation Ia).

Authors:  M Casado; M M O'Callaghan; R Montero; C Pérez-Cerda; B Pérez; P Briones; E Quintana; J Muchart; A Aracil; M Pineda; R Artuch
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

3.  Lymphatic edema in congenital disorders of glycosylation.

Authors:  Ruud Hj Verstegen; Miranda Theodore; Hans van de Klerk; Eva Morava
Journal:  JIMD Rep       Date:  2011-10-20

Review 4.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

5.  Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway.

Authors:  Tjitske Kleefstra; Saskia B Wortmann; Richard J T Rodenburg; Ernie M H F Bongers; Kinga Hadzsiev; Cees Noordam; Lambert P van den Heuvel; Willy M Nillesen; Katalin Hollody; Gabrielle Gillessen-Kaesbach; Martin Lammens; Jan A M Smeitink; Ineke van der Burgt; Eva Morava
Journal:  Eur J Hum Genet       Date:  2010-11-10       Impact factor: 4.246

Review 6.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

7.  Congenital disorder of glycosylation type Ia: heterogeneity in the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency.

Authors:  B Shanti; M Silink; K Bhattacharya; N J Howard; K Carpenter; M Fietz; P Clayton; J Christodoulou
Journal:  J Inherit Metab Dis       Date:  2009-04-27       Impact factor: 4.982

Review 8.  Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update.

Authors:  Jan Verheijen; Shawn Tahata; Tamas Kozicz; Peter Witters; Eva Morava
Journal:  Genet Med       Date:  2019-09-19       Impact factor: 8.822

9.  From discrete dilated cardiomyopathy to successful cardiac transplantation in congenital disorders of glycosylation due to dolichol kinase deficiency (DK1-CDG).

Authors:  Livia Kapusta; Nili Zucker; George Frenckel; Benjamin Medalion; Tuvia Ben Gal; Einat Birk; Hanna Mandel; Nadim Nasser; Sarah Morgenstern; Andreas Zuckermann; Dirk J Lefeber; Arjen de Brouwer; Ron A Wevers; Avraham Lorber; Eva Morava
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

10.  Non-functional alternative splicing caused by a Latino pathogenic variant in a case of PMM2-CDG.

Authors:  C A González-Domínguez; C E Villarroel; M Rodríguez-Morales; S Manrique-Hernández; A González-Jaimes; F Olvera-Rodriguez; K Beutelspacher; C Molina-Garay; K Carrillo-Sánchez; L L Flores-Lagunes; M Jiménez-Olivares; A Muñoz-Rivas; M E Cruz-Muñoz; H M Mora-Montes; R Salinas-Marín; C Alaez-Verson; I Martínez-Duncker
Journal:  Mol Genet Metab Rep       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.